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Received May 4, 2014; accepted October 6, 2014AbstractBackground: Considerable controversy surrounds the treatment of ampullary neoplasms. This report describes the authors' experiences regarding
the choice of either ampullectomy or pancreaticoduodenectomy for treatment of ampullary tumors.
Methods: Demographics, statistical findings concerning diagnosis, surgical risks including morbidity and mortality, and outcomes were evaluated
and compared between the ampullectomy and pancreaticoduodenectomy groups for ampullary tumors retrieved from a prospectively collected
computer database of 992 periampullary tumors resected during the period from 1965 to 2013.
Results: A total of 377 patients with ampullary tumors were included; 15 underwent ampullectomy and 362 underwent pan-
creaticoduodenectomy. The overall false-negative rate for diagnosis of ampullary malignancy was 11.2%, specificity was 50.0%, positive
predictive value was 98.3%, negative predictive value was 12.2%, and the overall accuracy was 87.6% (77.5% by preoperative endoscopic biopsy
and 83.9% by intraoperative frozen-section biopsy). Ampullectomy was associated with shorter postoperative stays and lower surgical morbidity.
There was no statistical difference observed between the two groups regarding surgical mortality, pancreatic leakage, or gastric atonia. The
tumor recurrence rate was lower after pancreaticoduodenectomy, but the difference between the groups was not significant. Overall, there was no
difference in survival observed between the two groups.
Conclusion: Because biopsy is not routinely reliable, pancreaticoduodenectomy is preferable to ampullectomy for an ampullary tumor of un-
certain diagnosis. Ampullectomy is associated with lower surgical morbidity and should therefore remain in the armamentarium of the
pancreatic surgeon when comorbidity precludes major surgery.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Two surgical procedures have historically been used in the
treatment of ampullary tumors: ampullectomy, a local resection
of the ampulla of Vater, was described in 1899 by Halsted,1 and
pancreaticoduodenectomy was introduced by Whipple et al in
1935.2 However, ampullectomy has not achieved widespreadConflicts of interest: The authors declare that there are no conflicts of interest
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assacceptance because of its lesser radicality and the higher rates of
tumor recurrence associated with it (range, 20e100%).3e6 By
contrast, pancreaticoduodenectomy (also known as the Whip-
ple procedure) is a more radical form of surgery and has long
been considered the only alternative for patients with malignant
periampullary diseases.7e10 In addition, many centers have
developed the expertise for reducing the surgical risks associ-
ated with pancreaticoduodenectomy, which is currently
considered the superior treatment option for benign or prema-
lignant diseases of the ampulla of Vater.7,9,10 Nonetheless,
pancreaticoduodenectomy is clearly associated with high peri-
operative morbidity, and the quality of life of patients after
undergoing this radical surgery is much poorer than that
following local resection with ampullectomy.8e10ociation. All rights reserved.
340 J.-H. Lai et al. / Journal of the Chinese Medical Association 78 (2015) 339e344Because it is characterized by more limited resection, lesser
morbidity, and lower surgical risk as compared with pan-
creaticoduodenectomy, ampullectomy represents a potentially
attractive alternative for removal of certain benign ampullary
lesions and may be more appropriate for those rare patients
with a malignancy and who are unfit for major surgery.7,8,10e12
A recent review of the literature revealed that the number of
patients undergoing ampullectomy is relatively small. Conse-
quently, the clinical features and outcomes for these patients
have not been well-described, indications for this procedure
remain controversial, and the limitations of this form of
resection remain unclear.6,8,11
This report presents the experiences of members of the
Department of Surgery, Taipei Veterans General Hospital
regarding ampullectomy and pancreaticoduodenectomy in the
treatment of ampullary tumors. The two surgical procedures
were evaluated and compared with respect to demographics,
clinical presentations, diagnostic accuracy, associated surgical
risks, and patient outcome.
2. Methods
Data on two series of consecutive patients, those who un-
derwent ampullectomy and those who underwent pan-
creaticoduodenectomy, were retrieved from a prospectively
collected computer database of 992 periampullary tumors
resected during the period from 1965 to 2013 at the Taipei
Veterans General Hospital. Informed consent was obtained
from each patient. The study protocol was approved by our
Institutional Review Board. We did not improperly disclose
any personal data of the patients, and furthermore there was no
safety concern for the patients in this study. Pan-
creaticoduodenectomy for radical tumor removal has been the
treatment of choice at this institution for ampullary tumors,
with ampullectomy reserved for patients at high surgical risk
or who refuse a more radical surgery.
Demographics, clinical presentations, statistical findings
concerning diagnosis, surgical risks including morbidity and
mortality, follow-up periods, and survival outcomes were eval-
uated and then compared between these two surgical groups.
Based on the definitions of the International Study Group on
Pancreatic Fistula,13 pancreatic leakage was defined as grade B
or C postoperative pancreatic fistula, and gastric atonia was
defined as grade B or C delayed gastric emptying according to
the definition by the International Study Group of Pancreatic
Surgery.14 Surgical mortality was defined as death occurring
perioperatively and within 30 days following surgery or during
the initial hospital stay if 30 or more days had elapsed.
Ampullectomy was performed to achieve a wide excision,
which included a portion of the duodenal wall, distal segments
of the distal common bile and pancreatic ducts, and a wedge of
pancreatic parenchyma. Resection margins of the biliary and
pancreatic ducts (frozen section) were sent for pathological
analysis to confirm that surgical resection was complete. To
reconstruct the defect, the pancreatic and common bile ducts
were sutured together in a common septum (common wall)
fashion, and the surrounding duodenal wall was thenreapproximated to the joined pancreatic and common duct
openings.
Pancreaticoduodenectomy was performed at this institution
with a standard resection and without extensive retroperitoneal
lymph node dissection. Whether the classic pan-
creaticoduodenectomy procedure would utilize either a distal
gastrectomy or a pylorus-preserving resection was generally
left to the discretion of the surgeon. A pancreaticogastrostomy
or pancreaticojejunostomy was chosen for pancreatic recon-
struction; vagotomy was not routinely performed.
Statistical analyses were performed using Statistical Prod-
uct and Service Solutions (SPSS) version 21.0 software (SPSS
Inc., IBM, Armonk, NY, USA). All continuous data are pre-
sented as median and mean ± standard deviation, and fre-
quencies are presented when appropriate to the type of data.
The mean values of continuous variables were compared using
a two-tailed Student t test. Nonparametric statistical tests were
used if the variables did not follow normal distribution. Cat-
egorical variables are presented as numbers and percentages,
and were compared using Pearson c2 test or Fisher exact test
contingency tables. The KaplaneMeier method was used for
the calculation of median survival and survival analysis. For
all analyses, a p value less than 0.050 was considered statis-
tically significant.
3. Results
Of the 992 patients in the database who underwent peri-
ampullary tumor resection, 377 with ampullary lesions were
enrolled in this study; of this total, 15 underwent ampullec-
tomy (Table 1) and 362 underwent pancreaticoduodenectomy.
Therefore, ampullectomy was performed in 1.5% (15/992) of
cases of resected periampullary tumors and 4.0% (15/377) of
cases of resected ampullary tumors. Reasons for selection of
ampullectomy included high surgical risk due to severe co-
morbidity in eight patients, obesity in two patients, and patient
preference due to the small size and unclear characteristics of
the tumor in five patients. Among the ampullectomy group,
eight cases were malignant and in two (25%) of these cases
death occurred due to tumor recurrence; the latter involved
carcinomatosis at 67 months following ampullectomy for a
pT2 ampullary adenocarcinoma in one patient and liver
metastasis at 88 months following ampullectomy for a carci-
noma in situ tumor (pTis) in the other. The cut margins for the
resected specimens were all proved to be free from malig-
nancy in the ampullectomy patients. No statistical difference
was observed between the ampullectomy and pan-
creaticoduodenectomy groups with respect to sex, age, dura-
tion of symptoms, tumor size, and serum tumor markers
including carbohydrate antigen 19-9 and carcinoembryonic
antigen. Regarding clinical presentation, more patients without
symptoms (20.0% vs. 3.6%, p ¼ 0.021) and fewer patients
with jaundice (33.3% vs. 76.0%, p ¼ 0.001) were observed in
the ampullectomy group as compared with the pan-
creaticoduodenectomy group (Table 2).
Table 3 presents the statistical parameters for diagnosis of
ampullary malignancy before resection. Forty-six (12.2%)
Table 1
Ampullectomy for ampullary lesions.
Case Age
(y)
Sex Tumor
size (cm)
Pathology a Complication Tumor
recurrence
Survival
time (mo)
Outcome
1 73 M 2.5 4 No No 86 Alive
2 83 F 3.5 1 (pT2) No No 31 Died of other cause
3 51 M 2 1 (pT2) No Yes
(carcinomatosis)
67 Died of disease
4 61 M 1.5 1 (pTis) No Yes
(liver metastasis)
88 Died of disease
5 70 M 1.5 5 No No 108 Alive
6 63 M 4 6 No No 195 Died of other cause
7 73 M 3 2 Yes (intra-abdominal bleeding) No 133 Died of other cause
8 64 M 2 2 Yes (wound infection) No 136 Died of other cause
9 85 M 3 2 No No 148 Alive
10 29 M 0.5 3 No No 95 Alive
11 72 M 3 1 (pT2) No No 40 Alive
12 80 M 2.5 1 (pTis) No No 38 Alive
13 69 M 3.5 1 (pT1) No No 18 Alive
14 69 F 1.5 1 (pTis) No No 6 Alive
15 79 F 3.5 1 (pT2) No No 6 Alive
a Pathology: 1 ¼ adenocarcinoma; 2 ¼ tubulovillous adenoma; 3 ¼ dysplasia; 4 ¼ leiomyoma; 5 ¼ ectopic pancreas; 6 ¼ adenomatous polyp;
pTis ¼ pathological carcinoma in situ.
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diagnosis in this study. The overall false-negative rate for
diagnosis was 11.2%; for diagnosis by preoperative endo-
scopic biopsy, the false-negative rate was 21.1% and forTable 2
Demographics and clinical presentations of ampullary lesions undergoing resectio
Total
(n ¼ 377)
Amp
(n ¼
Sex
Male 256 (67.9%) 12 (8
Female 121 (32.1%) 3 (30
Age (y)
Median 66 69
Range 29e90 29e8
Mean ± SD 64.9 ± 11.6 66.7
Duration of symptoms (mo)
Median 1 1
Range 0e120 0e96
Mean ± SD 2.6 ± 8.4 8.9 ±
Symptoms
No symptoms 16 (4.2%) 3 (20
Jaundice 280 (74.3%) 5 (33
Epigastric pain 167 (44.3%) 7 (46
Fever 134 (35.5%) 3 (20
Body weight loss 128 (34.0%) 2 (13
Nausea/vomiting 43 (11.4%) 3 (20
Size (cm)
Median 2.0 2.8
Range 0.4e10.0 0.5e
Mean ± SD 2.4 ± 1.4 2.5 ±
Serum CA 19-9 (U/mL)
Median 53.7 16.3
Range 0.6e64,562.0 4.9e
Mean ± SD 695.2 ± 4511.3 27.8
Serum CEA (ng/mL)
Median 3.2 1.4
Range 0.4e143.0 1.1e
Mean ± SD 4.9 ± 10.7 1.5 ±
CA 19-9 ¼ carbohydrate antigen 19-9; CEA ¼ carcinoembryonic antigen; SD ¼diagnosis by intraoperative frozen-section biopsy, the false-
negative rate was 14.4%. The overall sensitivity for diag-
nosis before resection, therefore, was 88.8%; sensitivity by
preoperative endoscopic biopsy was 77.9% and byn.
ullectomy
15)
Pancreaticoduodenectomy
(n ¼ 362)
p
0.404
0.0%) 244 (67.4%)
.0%) 118 (32.6%)
0.345
66
3 31e90
± 13.2 64.9 ± 11.6
0.430
1
0e120
25.3 2.4 ± 7.0
.0%) 13 (3.6%) 0.021
.3%) 275 (76.0%) 0.001
.7%) 160 (44.2%) > 0.99
.0%) 131 (36.2%) 0.274
.3%) 126 (34.8%) 0.100
.0%) 40 (11.0%) 0.395
0.857
2.0
3.5 0.4e10
1.1 2.4 ± 1.4
53.8 0.421
73.9 0.6e64,562.0
± 31.4 706.7 ± 4549.3
0.522
3.3
2.0 0.4e143.0
0.4 4.9 ± 10.7
standard deviation.
Table 3
Diagnosis of ampullary malignancy before resection.
Diagnosis of malignancy Sensitivity Specificity Positive
predictive value
Negative
predictive value
Accuracy
1. Preoperative endoscopic biopsy (n ¼ 275) 77.9% 62.5% 98.6% 7.8% 77.5%
2. Intraoperative frozen section (n ¼ 93) 85.6% 33.3% 97.5% 7.1% 83.9%
3. Overall before resection (1 þ 2) a (n ¼ 331) 88.8% 50.0% 98.3% 12.2% 87.6%
a Forty-six (12.2%) patients underwent resection without biopsy for pathological diagnosis.
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specificity was only 50.0%. The positive predictive value
reached as high as 98.3% but the negative predictive value was
only 12.2%. The overall accuracy was 87.6%; accuracy by
preoperative endoscopic biopsy was 77.5% and by intra-
operative frozen-section biopsy was 83.9%.
The length of the postoperative stay was significantly
shorter for the ampullectomy group as compared with the
pancreaticoduodenectomy group (median, 13 vs. 27 days,
p ¼ 0.021). Surgical morbidity was also lower for the
ampullectomy group as compared with the pan-
creaticoduodenectomy group (20.0% vs. 50.6%, p ¼ 0.032;
Table 4). No statistical differences were observed between the
two surgical groups with respect to surgical mortality,
pancreatic leakage, or gastric atonia. Although the tumor
recurrence rate was lower after pancreaticoduodenectomy, the
difference between the groups did not reach statistical signif-
icance for either overall (25.0% vs. 21.6%, p ¼ 0.671) or early
(pTis-2: 25.0% vs. 16.6%, p ¼ 0.608) ampullary adenocarci-
noma. No difference in survival was observed between the two
surgical techniques.Table 4
Surgical outcomes of resection for ampullary tumors.
Total
(n ¼ 377)
Ampull
(n ¼ 15
Length of stay (d)
Median 27 13
Range 7e383 7e60
Mean ± SD 34.5 ± 29.1 17.5 ±
Surgical mortality 35 (9.3%) 0
Surgical morbidity 186 (49.3%) 3 (20.0%
Pancreatic leakage 66 (17.5%) 1 (6.7%
Gastric atonia 19 (5.0%) 1 (6.7%
Recurrence after resectiona
Total (n ¼ 332) 72 (21.7%) 2 (25.0%
pTis-2 (n ¼ 261) 42 (16.7%) 2 (25.0%
Survival for all a (mo) n ¼ 332 n ¼ 8
Median 29.0 34.2
Range 0.9e364.9 4.7e88
Mean ± SD 56.5 ± 65.2 36.3 ±
5-y survival (%) 39.1 80.0
Survival for pTis-2 (mo) n ¼ 261 n ¼ 8
Median 32.1 34.2
Range 0.9e364.9 4.7e88
Mean ± SD 62.1 ± 69.8 36.3 ±
5-y survival (%) 47.2 80.0
pTis-2 ¼ pathological carcinoma in situ to T2 ampullary adenocarcinoma; SD ¼
a For adenocarcinoma only.4. Discussion
Ampullectomy is seldom considered the best treatment for
an ampullary tumor. In the present series, ampullectomy was
performed in only 4.0% of cases of ampullary tumor resection
and 1.5% of cases of periampullary tumor resection. Further-
more, there is no clear consensus for performing ampullec-
tomy. Surgical ampullectomy, as a method of local resection,
is generally considered acceptable for: (1) a benign or pre-
malignant ampullary tumor, (2) a carcinoma that is small in
size (<2 cm), pTis/pT1, well or moderately differentiated, not
extending more than 1 cm into the pancreatic or bile ducts, and
without nodal involvement, and (3) a small neuroendocrine
tumor.1,5,10,15,16 For the ampullectomy to be successful, how-
ever, the biopsy should prove reliable, the surgical risk(s)
should be minimal, and the surgery should be curative.
A prominent concern of surgeons considering ampullec-
tomy is the accuracy of biopsy. Distinguishing between
ampullary adenoma and adenocarcinoma before resection of
the tumor represents a considerable challenge. Because most
preoperative biopsies and biopsies of frozen sections obtainedectomy
)
Pancreaticoduodenectomy
(n ¼ 362)
p
27
8e383
13.3 35.3 ± 29.4 <0.001
35 (9.7%) 0.379
) 183 (50.6%) 0.032
) 65 (18.0%) 0.458
) 18 (5.0%) 0.547
) 70 (21.6%) 0.671
) 42 (16.6%) 0.608
n ¼ 324 0.563
28.9
.6 0.9e364.9
28.4 57.0 ± 65.9
40.1
n ¼ 253 0.745
32.1
.6 0.9e364.9
28.4 65.9 ± 70.6
46.5
standard deviation.
343J.-H. Lai et al. / Journal of the Chinese Medical Association 78 (2015) 339e344intraoperatively involve removal of small samples from the
superficial part of a larger ampullary tumor, the presence of
invasive disease could be missed.8,17 Recent findings reveal
that the accuracy of preoperative biopsy ranges from 62% to
81%, highlighting the insufficiency of preoperative biopsy
alone in the diagnosis of malignancy.6e8,10,17e22 Furthermore,
frozen-section analyses of resected specimens are thought to
fail to detect malignancy in 14% of cases.10,15 Therefore, it is
not routinely possible to exclude malignancy before resec-
tion.10 In the present study, the false-negative rate of biopsy in
the diagnosis of ampullary malignancy before resection was
11.2%, with a 21.1% false-negative rate obtained by preop-
erative endoscopic biopsy and 14.4% false-negative rate ob-
tained by intraoperative frozen-section biopsy. However, the
positive predictive value was found to be as high as 98.3%, the
negative predictive value was only 12.2%, and the overall
accuracy was 87.6%. Given that preoperative and intra-
operative biopsy findings cannot fully exclude the possibility
that an ampullary tumor is malignant, most surgeons are
reluctant to choose ampullectomy in preference to
pancreaticoduodenectomy.
Alternatively, ampullectomy as a method of local resection
is simpler to perform, has fewer long-term digestive sequelae,
and is associated with shorter hospitalization times and lower
surgical morbidity and mortality as compared with pan-
creaticoduodenectomy.6,7,15,23 The mortality and morbidity of
pancreaticoduodenectomy are a little bit higher than those for
pancreatic head cancer in experienced centers. The reasons for
that might be the pancreatic parenchyma of ampullary cancer
is softer (one of the risk factors for pancreatic leakage) than
that of pancreatic head cancer, and multiple surgeons are
involved in pancreaticoduodenectomy. The present study
confirms that ampullectomy is associated with lower surgical
morbidity and shorter hospital stays; in addition, ampullec-
tomy was not associated with surgical mortality in this study.
Therefore, ampullectomy should be more appropriate for pa-
tients with comorbid conditions precluding a major, more
radical operation such as pancreaticoduodenectomy.
When a potentially malignant mass is to be treated,
adequate tumor excision and accurate staging are paramount.
Therefore, if ampullectomy guarantees curability, this proce-
dure is preferable to pancreaticoduodenectomy in treatment of
early ampullary cancer. For the treatment of invasive cancer,
however, ampullectomy is clearly limited by its inabilities to
achieve a wide negative margin and to address lymph node
metastasis.3,22 Although some experts have advocated
ampullectomy for early stage (T1) invasive ampullary cancers,
most still believe that this procedure is inadequate for invasive
malignancy.10,16 In this regard, the lymph node positivity rate
is reported to be 28e42% in patients undergoing pan-
creaticoduodenectomy for T1 ampullary malignancies.7,10,19
In addition, 33% of patients are reported to have at least one
risk factor for failure after receiving ampullectomy for early
ampullary cancer; these factors include perineural invasion,
lymphovascular invasion, and extensive common bile duct or
pancreatic duct mucosal involvement.16 For those with pTis-2
ampullary adenocarcinoma, the case number in theampullectomy group is too small to reach any solid conclu-
sions, but the 5-year survival was 80% in the ampullectomy
group and 46.5% in the pancreaticoduodenectomy group. In
the present study, tumor recurrence was observed in two pa-
tients (25%) with ampullary malignancy: in one case, carci-
nomatosis was present at 67 months after ampullectomy for a
pT2 ampullary adenocarcinoma and in the other case, liver
metastasis was present at 88 months after ampullectomy for a
carcinoma in situ tumor (pTis). The clinical course for these
two patients with tumor recurrence was relatively indolent
after ampullectomy but both eventually died of the disease,
consistent with inadequate resection. In general, because
ampullectomy is associated with a greater risk of recurrence as
compared with pancreaticoduodenectomy, careful follow-up is
recommended for all patients who have been treated for
ampullary malignancy.8,17
In conclusion, because preoperative and intraoperative
frozen-section biopsies are not always reliable enough to exclude
ampullary malignancy, pancreaticoduodenectomy is preferable
to ampullectomy for a tumor with an uncertain diagnosis. As a
local resection, ampullectomy is associated with a high recur-
rence rate and questionable curability. However, ampullectomy
is a relatively simple and safe procedurewith lower surgical risks
as compared with pancreaticoduodenectomy. Ampullectomy
should therefore remain a viable alternative in the armamen-
tarium of the pancreatic surgeon for patients with comorbidities
precluding a major operation.
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